E.g., 12/10/2018
E.g., 12/10/2018

bioMerieux Webinar on Endotoxin Testing

30 October, 2018

Are you interested in understanding the use, applications and approval process of sustainable rFC tests for endotoxin?  

2018 Product Lists

16 July, 2018

bioMérieux reinforces its offering of High Medical Value immunoassay biomarkers with the acquisition of Astute Medical

05 April, 2018

Marcy l’Étoile, France – April 4th, 2018 – bioMérieux, a world leader in the field of in vitro diagnostics, announces today the acquisition of Astute Medical Inc., a company dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers. In particular, Astute developed the NEPHROCHECK® test, an FDA-cleared test for the early risk assessment of acute kidney injuries (AKI) based on the level of two biomarkers, IGFBP-7 (Insulin-like Growth Factor-Binding Protein-7) and TIMP-2 (Tissue Inhibitor Metalloproteinases-2).

AMR Declaration

15 November, 2017

Declaration by the In Vitro Diagnostics Industry on Tackling Antimicrobial Resistance – signed by Mr Belingard, Chairman of bioMérieux November 2017 

Pioneering Diagnostics